Upfront osimertinib — winner takes it all?

Overview of attention for article published in Nature Reviews Clinical Oncology, February 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 34 X users

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 41 X posts from 34 X users, with an upper bound of 164,040 followers.

RT @NatRevClinOncol: #ASCO20 If you are enjoying the discussion of ADAURA, you might want to read more about osimertinib in NSCLC in a rece…

#ASCO20 If you are enjoying the discussion of ADAURA, you might want to read more about osimertinib in NSCLC in a recent News and Views https://t.co/421ozDscK0

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 37 additional X posts.